The upcoming webinar, hosted by Xtalks, focuses on the shift from standard lipid nanoparticle (LNP) designs toward ligand-conjugated systems capable of avoiding hepatic sequestration. Speakers will analyze how modulating protein corona interactions and reducing ApoE-mediated uptake can redirect these particles to specific cell types. The session will cover technical approaches, including covalent conjugation and post-insertion methods, to ensure that ligand density and orientation remain stable during manufacturing.

Beyond formulation design, the discussion emphasizes the bridge between laboratory testing and preclinical results. Participants will examine how to utilize in vitro models to gather actionable data on receptor binding and functional delivery. The panel, featuring experts from Phosphorex, NOF Corporation, and Neosome Life Sciences, will also explore how to integrate biodistribution and immunogenicity datasets to select candidates with clear clinical potential. By aligning formulation development with rigorous functional evaluation, researchers aim to create a more reliable framework for navigating the transition from early-stage design to successful preclinical validation.